专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO0104335A3 HUMAN-BOVINE CHIMERIC RESPIRATORY SYNCYTIAL VIRUS VACCINES 审中-公开
标题翻译：人类猪流感呼吸道感染病毒疫苗
公开(公告)号：WO0104335A3
公开(公告)日：2002-12-19
申请号：PCT/US0017755
申请日：2000-06-23
申请人： US GOV HEALTH & HUMAN SERV , BUCHHOLZ URSULA , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S , KREMPL CHRISTINE D
发明人： BUCHHOLZ URSULA , COLLINS PETER L , MURPHY BRIAN R , WHITEHEAD STEPHEN S , KREMPL CHRISTINE D
IPC分类号： C12N15/09 , A61K39/00 , A61K39/12 , A61P11/00 , C07K14/14 , C12N7/00 , C12N7/04 , C12N15/86 , C12R1/93 , A61K38/17 , C12N15/62
CPC分类号： C12N7/00 , A61K39/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , C07K14/005 , C07K2319/00 , C12N15/86 , C12N2760/18522 , C12N2760/18534 , C12N2760/18543 , C12N2760/18561 , C12N2840/203
摘要： Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV "background" genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete "background" RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome. In preferred aspects of the invention, chimeric RSV incorporate a partial or complete bovine RSV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human RSV. Genes of interest include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment including a protein or portion thereof. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects.
摘要翻译：嵌合人 - 牛呼吸道合胞病毒（RSV）在人类和其他哺乳动物中具有感染性和减毒性，并且可用于引发抗RSV免疫应答的疫苗制剂中。还提供了分离的多核苷酸分子和掺入嵌合RSV基因组或抗原组的载体，其包括部分或完整的人或牛RSV“背景”基因组或与一个或多个异源基因或基因组片段不同的RSV菌株。本发明的嵌合人类牛RSV包括部分或完整的“背景”RSV基因组或在与一个或多个异源基因或基因组片段组合的人或牛RSV病毒株或亚组病毒之后衍生或构图的部分或完整的“背景” 的不同RSV株或亚组病毒形成人 - 牛嵌合RSV基因组或抗原组。在本发明的优选方面，嵌合RSV包含与来自人RSV的一个或多个异源基因或基因组片段组合的部分或完整的牛RSV背景基因组或反向异构体。感兴趣的基因包括任何NS1，NS2，N，P，M，SH，M2（ORF1），M2（ORF2），L，F或G基因或包含蛋白质或其部分的基因组片段。在本发明的人 - 牛嵌合RSV内提供了多种额外的突变和核苷酸修饰，以产生所需的表型和结构效果。

32. 发明申请

WO0142445A3 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS 审中-公开
标题翻译：使用重组对虾流感病毒（PIV）作为保护对抗由PIV和其他人类病原体引起的感染和疾病的媒介
公开(公告)号：WO0142445A3
公开(公告)日：2001-11-29
申请号：PCT/US0033293
申请日：2000-12-08
申请人： US HEALTH , MURPHY BRIAN R , COLLINS PETER L , SCHMIDT ALEXANDER C , DURBIN ANNA P , SKIADOPOULOS MARIO H , TAO TAO
发明人： MURPHY BRIAN R , COLLINS PETER L , SCHMIDT ALEXANDER C , DURBIN ANNA P , SKIADOPOULOS MARIO H , TAO TAO
IPC分类号： C12N15/09 , A61K39/00 , A61K39/12 , A61K39/145 , A61K39/205 , A61K39/245 , A61K48/00 , A61P37/02 , C07K14/115 , C12N7/00 , C12N15/86 , C12R1/93 , C12N15/45 , A61K39/155 , C12N5/10 , C12N15/62
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/5256 , C12N15/86 , C12N2760/18622 , C12N2760/18643
摘要： Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. In preferred aspects of the invention, chimeric PIV incorporate a partial or complete human, bovine, or human-bovine chimeric, PIV vector genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a heterologous PIV or non-PIV pathogen, wherein the chimeric virus is attenuated for use as a vaccine agent by any of a variety of mutations and nucleotide modifications introduced into the chimeric genome or antigenome.
摘要翻译：提供嵌合副流感病毒（PIV），其包含PIV载体基因组或反基因组以及异源PIV或非PIV病原体的一种或多种抗原决定簇。这些嵌合病毒在人和其他哺乳动物中是感染性和减毒性的，并且可用于引发针对一种或多种PIV或针对PIV和非PIV病原体的免疫应答的疫苗制剂。还提供了分离的多核苷酸分子和掺入嵌合PIV基因组或反基因组的载体，所述嵌合PIV基因组或反基因组包含与编码抗原决定簇的一个或多个异源基因或基因组区段组合或整合的部分或完整PIV载体基因组或反基因组，的异源PIV或非PIV病原体。在本发明的优选方面，嵌合PIV包含与来自异源PIV的一个或多个异源基因或基因组区段结合的部分或完整人，牛或人 - 牛嵌合PIV载体基因组或反基因组，或非PIV病原体，其中通过引入嵌合基因组或反基因组中的任何多种突变和核苷酸修饰，嵌合病毒减毒用作疫苗剂。

33. 发明申请

WO1997010846A1 NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS 审中-公开
标题翻译：将单克隆抗体中和到呼吸道感染病毒
公开(公告)号：WO1997010846A1
公开(公告)日：1997-03-27
申请号：PCT/US1996014937
申请日：1996-09-18
申请人： INTRACEL CORPORATION , THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , PILKINGTON, Glenn, R. , GILMOUR, Page, S. , CHANOCK, Robert, M. , CROWE, James, E., Jr. , MURPHY, Brian, R.
发明人： INTRACEL CORPORATION , THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
IPC分类号： A61K39/42
CPC分类号： C07K16/1027 , A61K38/00 , A61K39/00 , A61K48/00 , A61K51/1006 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/565 , G01N33/56983
摘要： The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratoy Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.
摘要翻译：本发明涉及鉴定和克隆抗呼吸综合征病毒的新型中和人单克隆抗体。本发明提供了这样的抗体，保留RSV结合能力的这些抗体片段，保留RSV结合能力的嵌合抗体以及包含这种抗体的药物组合物。本发明还提供了编码本发明的抗体的分离的核酸和用其转化的宿主细胞。最后，本发明提供了使用本发明的抗体和核酸的诊断和治疗方法。

34. 发明申请

WO2010003032A3 RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1S) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1 审中-公开
标题翻译：包含突变或缺失C蛋白的重组人类嗜血菌1型病毒（HPIV1S）在非洲绿色猴子和人类睫状体上皮细胞中减毒并且是HPIV1的潜在疫苗候选者
公开(公告)号：WO2010003032A3
公开(公告)日：2010-08-12
申请号：PCT/US2009049461
申请日：2009-07-01
申请人： US GOV HEALTH & HUMAN SERV , BARTLETT EMMALENE , COLLINS PETER L , SKIADOPOULOS MARIO H , MURPHY BRIAN R
发明人： BARTLETT EMMALENE , COLLINS PETER L , SKIADOPOULOS MARIO H , MURPHY BRIAN R
IPC分类号： C07K14/005
CPC分类号： C12N7/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/543 , C12N2760/18634 , C12N2760/18661
摘要： Two recently characterized live attenuated HPIV1 vaccine candidates, rHPIV1-CR84G/ ?170HNT553ALY942A and rHPIV1-CR84G/? 170HNT553AL? 1710-11, which contain temperature sensitive (ts) attenuating (att) and non-ts att mutations, were evaluated in a Human Airway Epithelium (HAE) model culture system and in vivo in African Green monkeys (AGM). The vaccine candidates were highly restricted in growth in HAE at permissive (32 o C) and restrictive (37 o C) temperatures. The viruses grew slightly better at 37 o C than at 32 oC, and rHPIV1-CR84G/ ?170HNT553ALY942A was less attenuated than rHPIV1-CR84G/ ?170HNT553AL ?1710-11. The level of replication in HAE correlated with that observed in African Green monkeys, suggesting that the HAE model is useful as a tool for pre-clinical evaluation of HPIV1 vaccines. A live attenuated HPIV1 vaccine candidate having a normal P/C gene structure of overlapping P and C open reading frames, but does not express any functional C protein, is found to highly attenuated in AGMs, and provides a significant immune response in AGMs.
摘要翻译：最近有两种特征性活减毒HPIV1候选疫苗，rHPIV1-CR84G /？170HNT553ALY942A和rHPIV1-CR84G /？ 170HNT553AL？在人类呼吸道上皮细胞（HAE）模型培养系统中和体内非洲绿猴（AGM）中评估含有温度敏感性（ts）减弱（att）和非ts att突变的1710-11。候选疫苗高度限制HAE在宽容（32℃）和限制性（37℃）温度下的生长。病毒在37℃时比在32℃时稍微好些，rHPIV1-CR84G /Δ170HNT553ALY942A比rHPIV1-CR84G /Δ170HNT553ALΔ1710-11弱。 HAE中的复制水平与在非洲绿猴中观察到的复制水平相关，表明HAE模型可用作HPIV1疫苗的临床前评估的工具。发现具有重叠的P和C开放阅读框但不表达任何功能性C蛋白的正常P / C基因结构的活的减毒HPIV1疫苗候选物在AGM中高度减毒，并且在AGM中提供显着的免疫应答。

35. 发明申请

WO2008022196A2 DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS 审中-公开
标题翻译：登革热疫苗组分的研制
公开(公告)号：WO2008022196A2
公开(公告)日：2008-02-21
申请号：PCT/US2007076004
申请日：2007-08-15
申请人： US GOV HEALTH & HUMAN SERV , WHITEHEAD STEPHEN S , BLANEY JOSEPH E , MURPHY BRIAN R
发明人： WHITEHEAD STEPHEN S , BLANEY JOSEPH E , MURPHY BRIAN R
IPC分类号： C12N7/00
CPC分类号： C12N7/045 , A61K2039/5254 , C07K14/005 , C07K14/1825 , C12N7/00 , C12N2770/24122 , C12N2770/24162
摘要： The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3' untranslated region (3'-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3'-UTR that removes sequence in the 5' direction as far as the 5' boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3'-UTR of a dengue virus of a first serotype with the 3'-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3'-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
摘要翻译：本发明涉及在3'非翻译区（3'-UTR）中含有突变的登革热病毒或嵌合登革热病毒，其包含在每一登革病毒血清型1中除去TL-2同源结构的α30突变， 2,3和4以及从3'-UTR中删除的〜30个突变的核苷酸除去5'方向上的序列，直到每个登革热病毒中TL-3同源结构的5'边界血清型1,2,3和4，或用第二血清型登革病毒的3'-UTR替代第一血清型登革病毒的3'-UTR，任选含有Δ30突变和核苷酸从3'-UTR缺失的Δ30突变的附加物; 和免疫原性组合物，诱导免疫应答的方法，以及产生登革热病毒或嵌合登革病毒的方法。

36. 发明申请

WO2003092592A3 DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3'-UTR OF DENGUE TYPES 1,2,3, AND 4, OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1,2,3, AND 4 审中-公开
公开(公告)号：WO2003092592A3
公开(公告)日：2003-11-13
申请号：PCT/US2003/013279
申请日：2003-04-25
申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , WHITEHEAD, Stephen, S. , MURPHY, Brian, R. , MARKOFF, Lewis , FALGOUT, Barry , BLANEY, Joseph , HANLEY, Kathryn
发明人： WHITEHEAD, Stephen, S. , MURPHY, Brian, R. , MARKOFF, Lewis , FALGOUT, Barry , BLANEY, Joseph , HANLEY, Kathryn
IPC分类号： C07H21/04
摘要： The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3'-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.

37. 发明申请

WO03043587A2 RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 1 (HPIVI) FROM CDNA AND USE OF RECOMBINANT HPIVI IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS 审中-公开
标题翻译：从CDNA恢复重组人淋巴瘤病毒1型（HPIVI）和在免疫组化中使用重组HPIVI和作为向量的免疫应答对抗PIV和其他人类病原体的免疫反应
公开(公告)号：WO03043587A2
公开(公告)日：2003-05-30
申请号：PCT/US0237688
申请日：2002-11-21
申请人： US SECRETARY DEPT OF HEALTH AN , MURPHY BRIAN R , COLLINS PETER L , SKIADOPOULOS MARIO H , NEWMAN JASON T
发明人： MURPHY BRIAN R , COLLINS PETER L , SKIADOPOULOS MARIO H , NEWMAN JASON T
IPC分类号： A61K20060101 , A61K35/76 , A61K39/155 , A61P31/14 , C07K14/115 , C12N7/00 , C12N7/01 , C12N7/04 , C12N15/45 , C12N15/86 , C12P21/04 , A61K
CPC分类号： C07K14/005 , A61K2039/525 , C12N7/00 , C12N15/86 , C12N2760/18622 , C12N2760/18643 , C12N2760/18661
摘要： Recombinant human parainfluenza virus type I (HPIVI) composiitions, formulations, and methods are provided. The recombinant HPIVI viruses and HPIVI chimeric and chimeric vector viruses provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, are useful in immunogenic composition s for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIVI genome or antigenome.
摘要翻译：提供重组人副流感病毒I型（HPIVI）组合物，制剂和方法。根据本发明提供的重组HPIVI病毒和HPIVI嵌合和嵌合载体病毒在许可哺乳动物受试者（包括人）中是感染性和减毒性的，可用于针对一种或多种非免疫原性引发针对一种或多种PIV的免疫应答的免疫原性组合物 -PIV病原体，或针对PIV和非PIV病原体。还提供了分离的多核苷酸分子和掺入重组HPIVI基因组或反基因组的载体。

38. 发明申请

WO0202605A3 ATTENUATED HUMAN-BOVINE CHIMERIC PARAINFLUENZA VIRUS (PIV) VACCINES 审中-公开
标题翻译：衰老人类血液流行性感冒病毒（PIV）疫苗
公开(公告)号：WO0202605A3
公开(公告)日：2003-01-09
申请号：PCT/US0121527
申请日：2001-07-05
申请人： US HEALTH , SKIADOPOULOS MARIO H , COLLINS PETER L , MURPHY BRIAN R , SCHMIDT ALEXANDER C
发明人： SKIADOPOULOS MARIO H , COLLINS PETER L , MURPHY BRIAN R , SCHMIDT ALEXANDER C
IPC分类号： A61K39/155 , C12N7/04 , C12N15/45 , C07K14/115 , C12N7/00
CPC分类号： C12N7/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , A61K2039/543 , A61K2039/544 , C12N2760/18634 , C12N2760/18661
摘要： Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV "background" genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete "background" PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome. In certain aspects of the invention, chimeric PIV incorporate a partial or complete human PIV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a bovine PIV, whereby the resultant chimeric virus is attenuated by virtue of host-range restriction. In alternate embodiments, human-bovine chimeric PIV incorporate a partial or complete bovine PIV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human PIV gene that encode a human PIV immunogenic protein, protein domain or epitope, for example encoded by PIV HN and/or F glycoprotein gene(s) or genome segment(s). Human-bovine chimeric PIV of the invention are also useful as vectors for developing vaccines against other pathogens. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric PIV of the invention to yield desired phenotypic and structural effects.
摘要翻译：嵌合人 - 牛副流感病毒（PIV）在人类和其他哺乳动物中具有感染性和减毒性，并且在疫苗制剂中单独使用或组合用于引发抗PIV免疫应答。还提供了分离的多核苷酸分子和掺入嵌合PIV基因组或抗原组的载体，其包括部分或完整的人或牛PIV“背景”基因组或反基因组，其与一个或多个异源基因或基因组片段组合或整合，不同的PIV。本发明的嵌合人牛PIV包括部分或完整的“背景”PIV基因组或反义基因组，其衍生自或构图在人或牛PIV病毒与一个或多个异源基因或不同基因组的基因组片段组合 PIV病毒形成人 - 牛嵌合PIV基因组或抗原组。在本发明的某些方面，嵌合PIV包含与牛PIV的一个或多个异源基因或基因组片段组合的部分或完整的人PIV背景基因组或反向异构体，由此得到的嵌合病毒被减弱的主机范围限制。在替代实施方案中，人 - 牛嵌合PIV掺入部分或完整的牛PIV背景基因组或与来自编码人PIV免疫原性蛋白质的蛋白质的人PIV基因的一个或多个异源基因或基因组片段组合的反义基因组结构域或表位，例如由PIV HN和/或F糖蛋白基因或基因组片段编码。本发明的人 - 牛嵌合PIV也可用作开发针对其他病原体的疫苗的载体。在本发明的人 - 牛嵌合PIV内提供了各种另外的突变和核苷酸修饰，以产生所需的表型和结构效果。

39. 发明申请

WO1998002530A1 PRODUCTION OF ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES 审中-公开
标题翻译：从克隆核苷酸序列产生减毒的呼吸道病毒疫苗
公开(公告)号：WO1998002530A1
公开(公告)日：1998-01-22
申请号：PCT/US1997012269
申请日：1997-07-15
申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES , MURPHY, Brian, R. , COLLINS, Peter, L. , WHITEHEAD, Stephen, S. , BUKREYEV, Alexander A. , JUHASZ, Katalin , TENG, Michael, N.
发明人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
IPC分类号： C12N07/04
CPC分类号： C07K14/005 , A61K39/00 , C12N7/00 , C12N2760/18522 , C12N2760/18561
摘要： Attenuated respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing specific mutations associated with attenuating phenotypes into wild-type or RSV which is incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive ( ts ) or cold adapted ( ca ) phenotype. Alternatively, recombinant RSV and vaccine compositions thereof incorporate attenuating and other mutations specifying desired structural and or phenotypic characteristics in an infectious RSV. Recombinant RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of a selected nucleotide sequence, gene, or gene segment in an infectious RSV clone. The immune system of an individual is stimulated to induce protection against natural RSV infection, or multivalently against infection by RSV and another pathogen, such as PIV, by administration of attenuated, biologically derived or recombinant RSV.
摘要翻译：减毒的呼吸道合胞病毒（RSV）及其疫苗组合物通过将与减毒表型有关的特异性突变引入野生型或RSV，通过冷通道或引入产生具有温度敏感性的病毒的突变（ ts）或冷适应（ ca）表型。或者，重组RSV及其疫苗组合物结合了在感染性RSV中指定所需结构和/或表型特征的减毒和其它突变。重组RSV包含通过在感染性RSV克隆中选择的核苷酸序列，基因或基因片段的插入，缺失，取代或重排而指定的所需突变。通过施用减毒的，生物衍生的或重组的RSV，刺激个体的免疫系统以诱导针对天然RSV感染的保护，或多重抗RSV和另一种病原体如PIV的感染。

40. 发明申请

WO1994006448A1 HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS 审中-公开
标题翻译：人类对呼吸道感染病毒的单克隆抗体中和
公开(公告)号：WO1994006448A1
公开(公告)日：1994-03-31
申请号：PCT/US1993008786
申请日：1993-09-16
申请人： THE SCRIPPS RESEARCH INSTITUTE , THE UNITED STATES GOVERNMENT as represented by ... , BURTON, Dennis, R. , BARBAS, Carlos, F., III , CHANOCK, Robert, M. , MURPHY, Brian, R. , CROWE, James, E., Jr.
发明人： THE SCRIPPS RESEARCH INSTITUTE , THE UNITED STATES GOVERNMENT as represented by ...
IPC分类号： A61K37/00
CPC分类号： A61K51/1006 , A61K38/00 , C07K16/1027 , C07K2319/00
摘要： Human monoclonal antibodies and fragments thereof which bind and neutralize respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell lines producing the monoclonal antibodies.
摘要翻译：公开了结合和中和呼吸道合胞病毒（RSV）抗原亚组A和B的人单克隆抗体及其片段。还公开了使用单克隆抗体以及产生单克隆抗体的细胞系的诊断和免疫治疗方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式